Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) is an indication for drug development with over 90 pipeline drugs currently active. According to GlobalData, preregistered drugs for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) have a 66.67% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) overview
Waldenstrom macroglobulinemia, one of the malignant monoclonal gammopathies, is a chronic, indolent, lymphoproliferative disorder. It is characterized by the presence of a high level of a macroglobulin (immunoglobulin M [IgM]), elevated serum viscosity, and the presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenström macroglobulinemia is considered to be a lymphoplasmacytic lymphoma, as defined by the Revised European American Lymphoma Classification (REAL) and World Health Organization (WHO) classification.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.